Citations (35)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Kentaro Machida, Tomotaka Kawayama, Masaharu Kinoshita, Masakazu Ichinose, Tohru Tsuda, Shohei Takata, Hiroshi Koto, Makoto Yoshida, Yoshinori Ashihara, Masaru Kawashima, Hideaki Suna & Hiromasa Inoue. (2019) Imidafenacin, An Orally Active Muscarinic Receptor Antagonist, Improves Pulmonary Function In Patients With Chronic Obstructive Pulmonary Disease: A Multicenter, Randomized, Double-Blind, Placebo-Controlled 3×3 Crossover Phase II Trial. International Journal of Chronic Obstructive Pulmonary Disease 14, pages 2175-2184.
Read now
Read now
Krithika Rajagopalan, Lisa Bloudek, Jessica Marvel, Carole Dembek & Abhishek Kavati. (2018) Cost-effectiveness of twice-daily indacaterol/glycopyrrolate inhalation powder for the treatment of moderate to severe COPD in the US. International Journal of Chronic Obstructive Pulmonary Disease 13, pages 3867-3877.
Read now
Read now
Mohamed Ismail Abdul Aziz, Ling Eng Tan, David Bin-Chia Wu, Fiona Pearce, Gerald Seng Wee Chua, Liang Lin, Ping-Tee Tan & Kwong Ng. (2018) Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis. International Journal of Chronic Obstructive Pulmonary Disease 13, pages 3203-3231.
Read now
Read now
Donald P Tashkin & Nicholas J Gross. (2018) Inhaled glycopyrrolate for the treatment of chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease 13, pages 1873-1888.
Read now
Read now
Anthony D D’Urzo, Peter Kardos & Russell Wiseman. (2018) Practical considerations when prescribing a long-acting muscarinic antagonist for patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease 13, pages 1089-1104.
Read now
Read now
Mark A. Mastrodicasa, Christopher A. Droege, Aaron M. Mulhall, Neil E. Ernst, Ralph J. Panos & Muhammad A. Zafar. (2017) Long acting muscarinic antagonists for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs. Expert Opinion on Investigational Drugs 26:2, pages 161-174.
Read now
Read now
Oskar Eklund, Faraz Afzal, Fredrik Borgström, Jason Flavin, Andrew Ternouth, Maria Eugenia Ojanguren, Carlos Crespo & Mike Baldwin. (2016) Cost-effectiveness of tiotropium versus glycopyrronium in moderate to very severe chronic obstructive pulmonary disease in Canada, Spain, Sweden, and the UK. ClinicoEconomics and Outcomes Research 8, pages 243-252.
Read now
Read now
Afisi Segun Ismaila, Eline L Huisman, Yogesh Suresh Punekar & Andreas Karabis. (2015) Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysis. International Journal of Chronic Obstructive Pulmonary Disease 10, pages 2495-2517.
Read now
Read now
Eline L Huisman, Sarah M Cockle, Afisi S Ismaila, Andreas Karabis & Yogesh Suresh Punekar. (2015) Comparative efficacy of combination bronchodilator therapies in COPD: a network meta-analysis. International Journal of Chronic Obstructive Pulmonary Disease 10, pages 1863-1881.
Read now
Read now
Andreas Karabis, Michelle Mocarski, Indra Eijgelshoven & Gert Bergman. (2014) Economic evaluation of aclidinium bromide in the management of moderate to severe COPD: an analysis over 5 years. ClinicoEconomics and Outcomes Research 6, pages 175-185.
Read now
Read now
Emily M. Armstrong, Bradley M. Wright, Allison Meyer, Courtney S. Watts & Kristi W. Kelley. (2014) The Role of Aclidinium Bromide in the Treatment of Chronic Obstructive Pulmonary Disease. Hospital Practice 42:4, pages 99-110.
Read now
Read now
Maria Gabriella Matera, Paola Rogliani & Mario Cazzola. (2014) Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy 15:7, pages 961-977.
Read now
Read now
Articles from other publishers (23)
Felisbela Gomes & Shih-Lung Cheng. (2023) Pathophysiology, Therapeutic Targets, and Future Therapeutic Alternatives in COPD: Focus on the Importance of the Cholinergic System. Biomolecules 13:3, pages 476.
Crossref
Crossref
Yasuhito Suzuki, Suguru Sato, Kento Sato, Sumito Inoue & Yoko Shibata. (2022) Treatment efficacy of LAMA versus placebo for stable chronic obstructive pulmonary disease: A systematic review and meta-analysis. Respiratory Investigation 60:1, pages 108-118.
Crossref
Crossref
Lu Qin, Di You, Guoqing Zhao, Longyun Li & Shishun Zhao. (2021) A comparison of analgesic techniques for total knee arthroplasty: A network meta-analysis. Journal of Clinical Anesthesia 71, pages 110257.
Crossref
Crossref
Andreas Heinecke, Marta Tallarita & Maria De Iorio. (2020) Bayesian splines versus fractional polynomials in network meta-analysis. BMC Medical Research Methodology 20:1.
Crossref
Crossref
Marta Tallarita, Maria De Iorio & Gianluca Baio. (2019) A comparative review of network meta‐analysis models in longitudinal randomized controlled trial. Statistics in Medicine 38:16, pages 3053-3072.
Crossref
Crossref
Kristof Faes, Joachim Cohen & Lieven Annemans. (2018) Resource Use During the Last Six Months of Life Among COPD Patients: A Population-Level Study. Journal of Pain and Symptom Management 56:3, pages 318-326.e7.
Crossref
Crossref
David M. Halpin, Alan G. Kaplan & Richard K. Russell. (2017) Why choose tiotropium for my patient? A comprehensive review of actions and outcomes versus other bronchodilators. Respiratory Medicine 128, pages 28-41.
Crossref
Crossref
Kevin Marsh, Erica Zaiser, Panagiotis Orfanos, Suzanne Salverda, Teresa Wilcox, Shawn Sun & Shailja Dixit. (2017) Evaluation of COPD Treatments: A Multicriteria Decision Analysis of Aclidinium and Tiotropium in the United States. Value in Health 20:1, pages 132-140.
Crossref
Crossref
Donald P. Tashkin, Eric D. Bateman, Paul Jones, Valentina B. Zubek, Norbert Metzdorf, Dacheng Liu, Thomas Leonard, Emmanuelle Clerisme-Beaty & Robert A. Wise. (2016) Consistent improvement in health-related quality of life with tiotropium in patients with chronic obstructive pulmonary disease: Novel and conventional responder analyses. Respiratory Medicine 120, pages 91-100.
Crossref
Crossref
Tara Rheault, Sanjeev Khindri, Mitra Vahdati-Bolouri, Alison Church & William A. Fahy. (2016)
A randomised, open-label study of umeclidinium
versus
glycopyrronium in patients with COPD
. ERJ Open Research 2:2, pages 00101-2015.
Crossref
Crossref
Silvia Sommariva, Aureliano P. Finch & Claudio Jommi. (2016) The assessment of new drugs for asthma and COPD: a Delphi study examining the perspectives of Italian payers and clinicians. Multidisciplinary Respiratory Medicine 11:1.
Crossref
Crossref
Oskar Eklund, Faraz Afzal & Fredrik Borgström. (2015) Cost-effectiveness of tiotropium versus usual care and glycopyrronium in the treatment of chronic obstructive pulmonary disease in Sweden. Cost Effectiveness and Resource Allocation 13:1.
Crossref
Crossref
Philippe Devillier, Eric Garrigue, Guillaume D’Auzers, Nicolas Monjotin, Thomas Similowski & Thierry Clerc. (2015) V0162 a new long-acting bronchodilator for treatment of chronic obstructive lung diseases: preclinical and clinical results. Respiratory Research 16:1.
Crossref
Crossref
Andrea C Tricco, Lisa Strifler, Areti-Angeliki Veroniki, Fatemeh Yazdi, Paul A Khan, Alistair Scott, Carmen Ng, Jesmin Antony, Kelly Mrklas, Jennifer D'Souza, Roberta Cardoso & Sharon E Straus. (2015) Comparative safety and effectiveness of long-acting inhaled agents for treating chronic obstructive pulmonary disease: a systematic review and network meta-analysis. BMJ Open 5:10, pages e009183.
Crossref
Crossref
Paola Rogliani, Luigino Calzetta, Josuel Ora, Roberto Lipsi, Andrea Segreti, Maria Gabriella Matera & Mario Cazzola. (2015) Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi. European Journal of Pharmacology 761, pages 383-390.
Crossref
Crossref
Leire Braceras & Isabel Elizondo. (2014) Análisis de minimización de costes y del impacto sobre el presupuesto de la Comunidad Autónoma del País Vasco del tratamiento de la enfermedad pulmonar obstructiva crónica moderada a grave con bromuro de aclidinio en lugar de bromuro de tiotropio. PharmacoEconomics Spanish Research Articles 12:2, pages 39-45.
Crossref
Crossref
Yuji Oba & Nazir A. Lone. (2015) Comparative efficacy of long-acting muscarinic antagonists in preventing COPD exacerbations: a network meta-analysis and meta-regression. Therapeutic Advances in Respiratory Disease 9:1, pages 3-15.
Crossref
Crossref
Tzahit Simon-Tuval & Nimrod Maimon. (2015) Tiotropium as part of inhaled polytherapy: Adherence and associated health-care utilization. Respirology 20:2, pages 304-311.
Crossref
Crossref
Han Ni, Zay Soe & Soe Moe. (2014) Aclidinium bromide for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2015:4.
Crossref
Crossref
Gülmisal Güder & Frans H. Rutten. (2014) Comorbidity of Heart Failure and Chronic Obstructive Pulmonary Disease: More than Coincidence. Current Heart Failure Reports 11:3, pages 337-346.
Crossref
Crossref
Richard E. Russell. (2014) Chronic obstructive pulmonary disease. Current Opinion in Pulmonary Medicine 20:2, pages 127-131.
Crossref
Crossref
A. Kirsten & H. Watz. (2014) LABA, LAMA und KombinationenLABA, LAMA and combinations. Der Pneumologe 11:2, pages 127-134.
Crossref
Crossref
G. Deslée. (2013) Bronchodilatateurs dans la BPCO : quoi de neuf ?. Revue des Maladies Respiratoires Actualités 5:6, pages 619-621.
Crossref
Crossref